Evaluation of clinically relevant glutamate pathway inhibitors in in vitro model of Huntington's disease

@article{Wu2006EvaluationOC,
  title={Evaluation of clinically relevant glutamate pathway inhibitors in in vitro model of Huntington's disease},
  author={Jun Wu and Tie-Shan Tang and Ilya B. Bezprozvanny},
  journal={Neuroscience Letters},
  year={2006},
  volume={407},
  pages={219-223}
}
View on Elsevier
www4.utsouthwestern.edu
55 Citations
Highly Influential Citations
2
Background Citations
22
Methods Citations
10
Results Citations
7

Figures and Tables from this paper

55 Citations

Citation Type

Citation Type

Neuroprotective Effect of EDR Peptide in Mouse Model of Huntington's Disease
TLDR
The data obtained prompt EDR peptide capability to restore the morphology of spines in striatum neurons in Huntington’s disease (HD) mouse model and the proposed model suggests that E DR peptide binds specific binding site oligo (dCG) along the DNA minor groove.
Neuronal store-operated calcium entry pathway as a novel therapeutic target for Huntington's disease treatment.
Evaluation of Dimebon in cellular model of Huntington's disease
TLDR
The results suggest that Ca2+ and mitochondria stabilizing effects may, in part, be responsible for beneficial clinical effects of Dimebon.
Experimental models of HD and reflection on therapeutic strategies.
Corticostriatal circuit dysfunction in Huntington's disease: intersection of glutamate, dopamine and calcium.
TLDR
The most current findings that implicate glutamate, dopamine and calcium signaling in this system and how they work in concert to disrupt corticostriatal function are summarized and therapeutic strategies related to altered corticOSTriatal signaling in HD are highlighted.
Dopaminergic Signaling and Striatal Neurodegeneration in Huntington's Disease
TLDR
The results suggest that dopamine signaling pathway plays an important role in HD pathogenesis and that antagonists of dopamine pathway such as tetrabenazine or dopamine receptor blockers may have a therapeutic potential for treatment of HD beyond well established “symptomatic” benefit.
Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments
TLDR
Successful neuroprotective therapy for Huntington's disease patients is likely to involve a combined approach targeting both cellular and molecular mediators that account for the toxicity of mutated huntingtin.
A mitochondrial basis for Huntington’s disease: therapeutic prospects
TLDR
Targeting mitochondria for their protection, while addressing symptomatic recovery, holds a great potential to tone down the progression of the disease, and to provide better relief to the patients and caretakers.
Novel targets for Huntington’s disease: future prospects
  • S. Mason, R. Barker
  • Biology, Psychology
    Degenerative neurological and neuromuscular disease
  • 2016
TLDR
The status of, and supporting evidence for, potential novel treatments of HD that are currently under development or have reached the level of early Phase I/II clinical trials are discussed.
Dantrolene is neuroprotective in Huntington's disease transgenic mouse model
TLDR
The hypothesis that deranged Ca2+ signaling plays an important role in HD pathology is supported and the RyanR inhibitors and Ca2- signaling stabilizers such as dantrolene should be considered as potential therapeutics for the treatment of HD and other polyQ-expansion disorders.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 26 REFERENCES
The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease.
TLDR
It is suggested that memantine treatment of HD may be useful in terms of retardation of the progression of the disorder.
Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease
TLDR
Investigating its potential neuroprotective effects in this mouse model found that survival time in the riluzole group was significantly increased in comparison to placebo‐treated transgenic controls, and progressive weight loss was delayed and significantly reduced by rILuzole treatment.
Deranged neuronal calcium signaling and Huntington disease.
Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease
Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease.
TLDR
A pathway directly linking disturbedCa2+ signaling and degeneration of MSN in the caudate nucleus in HD is described and it is suggested that Ca2+ and MPTP blockers may have a therapeutic potential for treatment of HD.
Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines
TLDR
It is shown that lymphoblast mitochondria from patients with HD have a lower membrane potential and depolarize at lower calcium loads than do mitochondriaFrom controls, and mitochondrial calcium abnormalities occur early in HD pathogenesis and may be a direct effect of mutant huntingtin on the organelle.
Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond
  • S. Lipton
  • Biology
    Nature Reviews Drug Discovery
  • 2006
TLDR
The molecular basis for memantine efficacy in neurological diseases that are mediated, at least in part, by overactivation of NMDARs, producing excessive Ca2+ influx through the receptor's associated ion channel and consequent free-radical formation is reviewed.
Increased Sensitivity to N-Methyl-D-Aspartate Receptor-Mediated Excitotoxicity in a Mouse Model of Huntington's Disease
Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease
Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease.
TLDR
The natural history of HD-related changes in the YAC128 mice has been defined, demonstrating the presence of huntingtin inclusions after the onset of behavior and neuropathological changes and making it an ideal mouse model for the assessment of neuroprotective and other therapeutic interventions.
...
1
2
3
...